Antitumor effect of cotylenin A plus interferon-α: Possible therapeutic agents against ovary carcinoma

Gynecologic Oncology

Volumn 99, Issue 3, 2005, Pages 680-688

  Honma, Yoshio ^a,b   Kasukabe, Takashi ^a   Yamori, Takao ^c   Kato, Nobuo ^d   Sassa, Takeshi ^e  

^a SAITAMA CANCER CENTER   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e YAMAGATA UNIVERSITY   (Japan)

Author keywords

Antitumor agent; Apoptosis; Combination therapy; Cotylenin A; Interferon ; Ovary carcinoma; TRAIL

Indexed keywords

ALPHA INTERFERON; CISPLATIN; COLLAGEN GEL; COTYLENIN A; DIFFERENTIATION INDUCING FACTOR; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL CULTURE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; XERORADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COLLAGEN; DITERPENES; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; INTERFERON-ALPHA; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 28044431806     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.07.015     Document Type: Article

References (24)

1. M. Chawla-Sarkar, D.J. Lindner, and Y.-F. Liu Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis Apoptosis 8 2003 237 249
2. Y. Honma, Y. Onozuka, J. Okabe-Kado, T. Kasukabe, and M. Hozumi Hemin enhances the sensitivity of erythroleukemia cells to 1-β-d- arabinofuranosylcytosine by both activation of deoxycytidine kinase and reduction of cytidine deaminase activity Cancer Res. 51 1991 4535 4538
3. J. Okabe-Kado, M. Hayashi, Y. Honma, M. Hozumi, and T. Tsuruo Inhibition by erythroid differentiation factor (activin A) of P-glycoprotein expression in multidrug-resistant human K562 erythroleukemia cells Cancer Res. 51 1991 2582 2586
4. D.M. Moore, D.V. Kalvakolanu, and S.M. Lippman Retinoic acid and interferon in human cancer: mechanistic and clinical studies Semin. Hematol. 31 1994 31 37
5. P.C. Adamson, G. Reaman, and J.Z. Finklestein Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-α2a in pediatric patients with refractory cancer J. Clin. Oncol. 15 1997 3330 3337
6. W.M. Stadler, T. Kuzel, M. Dumas, and N.J. Vogelzang Multicenter phase II trial of interleukin-2, interferon-α, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma J. Clin. Oncol. 16 1998 1820 1825
7. I. Goto, Y. Yamamoto-Yamaguchi, and Y. Honma Enhancement of sensitivity of human lung adenocarcinoma cells to growth-inhibitory activity of interferonα by differentiation-inducing agents Br. J. Cancer 74 1996 546 554
8. Y. Honma, Y. Ishii, Y. Yamamoto-Yamaguchi, T. Sassa, K. Asahi, and A. Cotylenin A differentiation-inducing agent, and interferon-α cooperatively induce apoptosis and have an antitumor effect of human non-small cell lung carcinoma cells in nude mice Cancer Res. 63 2003 3659 3666
9. K. Yamada, Y. Honma, and K. Asahi Differentiation of human acute myeloid leukaemia cells in primary culture in response to A. cotylenin, a plant growth regulator Br. J. Haematol. 114 2001 814 821
10. Y. Honma Cotylenin A-A plant growth regulator as a differentiation- inducing agent against myeloid leukemia Leuk. Lymphoma 43 2002 1169 1178
11. T. Sassa, T. Tojyo, and K. Munakata Isolation of a new plant growth substance with cytokinin-like activity Nature 224 1970 379
12. T. Sassa, T. Ooi, M. Nukina, M. Ikeda, and N. Kato Structural confirmation of A. cotylenin, a novel fusicoccane-diterpene glycoside with potent plant growth-regulating activity from Cladosporium fungus sp. 501-7W Biosci. Biotechnol. Biochem. 62 1998 1815 1818
13. Y. Honma, Y. Ishii, T. Sassa, and K. Asahi Treatment of human promyelocytic leukemia in the SCID mouse model with A. cotylenin, an inducer of myelomonocytic differentiation of leukemia cells Leuk. Res. 27 2003 1019 1025
14. Y. Yamamoto-Yamaguchi, J. Okabe-Kado, T. Kasukabe, and Y. Honma Induction of apoptosis by combined treatment with differentiation-inducing agents and interferon-α in human lung cancer cells Anticancer Res. 23 2003 2537 2548
15. T. Yamori, A. Matsunaga, and S. Sato Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel Cancer Res. 59 1999 4042 4049
16. T. Yamori Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics Cancer Chemother. Pharmacol. 52 Suppl 1 2003 74 79
17. H. Kobayashi, M. Higashiyama, and K. Minamigawa Examination of in vitro chemosensitivity test using collagen gel droplet culture method with colorimetric endpoint quantification Jpn. J. Cancer Res. 92 2001 203 210
18. Y. Takamura, H. Kobayashi, and T. Taguchi Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers Int. J. Cancer 98 2002 450 455
19. E.J. Freireich, R.A. Gehan, D.A. Rall, L.H. Schmidt, and H.E. Skipper Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man Cancer Chemother. Rep. 50 1966 219 244
20. C. Oecking, C. Eckerskorn, and E.W. Weiler The fusicoccin receptor of plants is a member of the 14-3-3 superfamily of eukaryotic regulatory proteins FEBS Lett. 352 1994 163 166
21. J.M. Lancaster, R. Sayer, and C. Blanchette High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival Clin. Cancer Res. 9 2003 762 766
22. R.S. Freedman, J.U. Gutterman, and F.N. Rutledge Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma J. Biol. Response Modif. 2 1983 133 138
23. N. Einhorn, P. Ling, S. Einhorn, and H. Strander A phase II study on escalating interferon doses in advanced ovarian carcinoma Am. J. Clin. Oncol. 11 1988 3 6
24. G.D. Hall, J.M. Brown, and R.E. Coleman Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomized phase III study Br. J. Cancer 91 2004 621 626